Showing results (2001-2010 of 3,105) with videos related to

Sort By:
Pageof 311
Drug Safety|March 4, 2020
Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic ReviewFatema A Alqenae, Douglas Steinke, Richard N Keers
Drug Safety|March 1, 2020
Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical UseRebecca N Jerome, Meghan Morrison Joly, Nan Kennedy, et al.
Drug Safety|January 17, 2019
Adverse Drug Event Detection from Electronic Health Records Using Hierarchical Recurrent Neural Networks with Dual-Level EmbeddingSusmitha Wunnava, Xiao Qin, Tabassum Kakar, et al.
Drug Safety|January 17, 2019
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in OncologyRashmi R Shah
Drug Safety|January 17, 2019
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung CancerDanilo Rocco, Ciro Battiloro, Luigi Della Gravara, et al.
Drug Safety|January 17, 2019
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in OncologyRashmi R Shah, Devron R Shah
Drug Safety|January 17, 2019
Safety and Tolerability of Antibody-Drug Conjugates in CancerAnna Wolska-Washer, Tadeusz Robak
Drug Safety|January 17, 2019
Safety and Tolerability of c-MET Inhibitors in CancerAlberto Puccini, Nagore I Marín-Ramos, Francesca Bergamo, et al.
Drug Safety|November 4, 2019
Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit-Harm of Drugs Received During Clinical StudiesAdam Gater, Matthew Reaney, Amy Findley, et al.
Drug Safety|January 8, 2020
Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity MonitoringHani Shamseddeen, Eduardo Vilar-Gomez, Naga Chalasani, et al.
Pageof 311